An Economic Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in the Nordics: Norway, Sweden, and Finland
Author(s)
Pollock R1, Muduma G2
1Covalence Research Ltd., London, LON, UK, 2Pharmacosmos A/S, Holbæk, Denmark
OBJECTIVES Iron deficiency anemia (IDA) is a common outcome of inflammatory bowel disease (IBD), arising from the combined effects of gastrointestinal blood loss and reduced iron absorption. Given this, intravenous (IV) iron should be considered first-line treatment in patients with clinically active IBD. The present study evaluated the budget impact of administering IV iron with ferric derisomaltose (FDI) versus ferric carboxymaltose (FCM) in patients with IDA and IBD in Norway, Sweden, and Finland. METHODS A cohort-level model of iron need was developed using a bivariate distribution of hemoglobin and bodyweight based on observational data from a multi-country Scandinavian study of patients with IDA and IBD. The base case analysis was conducted over 5 years in patients with IDA with mean bodyweight of 75.4 kg (SD 17.4 kg) and hemoglobin levels of 10.8 g/dL (SD 1.4 g/dL). Infusion costs were modeled using diagnosis-related groups. Sensitivity analyses were performed around different patient characteristics, care settings, and retreatment frequencies, and probabilistic sensitivity analyses were conducted. RESULTS Using FDI required 1.2 infusions to correct the mean iron deficit, compared with 1.6 infusions with FCM. In Norway, the per-patient cost of iron replenishment over five years was estimated to be NOK20,767 with FCM versus NOK15,799 with FDI, reflecting a cost saving of NOK4,968 or 23.9%. In Finland, projected costs decreased from EUR3,075 with FCM to EUR2,339 with FDI, reflecting a cost saving of EUR736 per patient. In Sweden, costs decreased from SEK27,760 with FCM to SEK21,119 with FDI, a reduction of 23.9% CONCLUSIONS Using FDI in place of FCM resulted in a marked reduction in the number of infusions required to correct iron deficits in patients with IDA and IBD. The reduction in infusions was accompanied by substantial cost savings relative to FCM over 5 years across all three Nordic countries evaluated.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PSY9
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Drugs, Gastrointestinal Disorders, Systemic Disorders/Conditions